Mr. Shkreli has spurred or added momentum to various congressional investigations into drug prices. But some, like one by the Senate Special Committee on Aging, are focused on Turing and Valeant, not on prices of new drugs or the steady price increases of nearly new drugs.
“Some of the companies that have been the focus of our investigation look more like hedge funds than they do traditional pharmaceutical companies,” the committee’s chairwoman, Senator Susan Collins, Republican of Maine, said at a hearing on Dec. 9.
That is music to the ears of the more conventional, research-oriented drug companies.